about
Origin and therapy for hypertriglyceridaemia in type 2 diabetesOxidized LDL and small LDL particle size are independently predictive of a selective defect in microcirculatory endothelial function in type 2 diabetesNDRG1 interacts with APO A-I and A-II and is a functional candidate for the HDL-C QTL on 8q24.Effect of ezetimibe on hepatic fat, inflammatory markers, and apolipoprotein B-100 kinetics in insulin-resistant obese subjects on a weight loss dietMechanism of action of a peroxisome proliferator-activated receptor (PPAR)-delta agonist on lipoprotein metabolism in dyslipidemic subjects with central obesity.Association of adiponectin and resistin with adipose tissue compartments, insulin resistance and dyslipidaemia.Lipoprotein kinetics in the metabolic syndrome: pathophysiological and therapeutic lessons from stable isotope studiesLipoprotein transport in the metabolic syndrome: methodological aspects of stable isotope kinetic studies.Thematic review series: patient-oriented research. Design and analysis of lipoprotein tracer kinetics studies in humans.Fish oils, phytosterols and weight loss in the regulation of lipoprotein transport in the metabolic syndrome: lessons from stable isotope tracer studies.Dose-dependent effect of rosuvastatin on VLDL-apolipoprotein C-III kinetics in the metabolic syndromeMenopausal Status and Abdominal Obesity Are Significant Determinants of Hepatic Lipid Metabolism in Women.Plasma apolipoprotein C-III transport in centrally obese men: associations with very low-density lipoprotein apolipoprotein B and high-density lipoprotein apolipoprotein A-I metabolism.Atorvastatin and fenofibrate have comparable effects on VLDL-apolipoprotein C-III kinetics in men with the metabolic syndrome.Regulatory effects of fenofibrate and atorvastatin on lipoprotein A-I and lipoprotein A-I:A-II kinetics in the metabolic syndrome.Effect of weight loss on HDL-apoA-II kinetics in the metabolic syndrome.Therapeutic regulation of apoB100 metabolism in insulin resistance in vivo.Postprandial lipoprotein metabolism in familial hypercholesterolemia: thinking outside the box.Postprandial hypertriglyceridemia and cardiovascular disease: current and future therapies.Demystifying the management of hypertriglyceridaemia.Critical review of non-statin treatments for dyslipoproteinemia.The metabolic and pharmacologic bases for treating atherogenic dyslipidaemia.Pathogenesis and management of the diabetogenic effect of statins: a role for adiponectin and coenzyme Q10?Factorial Effects of Evolocumab and Atorvastatin on Lipoprotein Metabolism.Recent explanatory trials of the mode of action of drug therapies on lipoprotein metabolism.Triglyceride-rich lipoprotein metabolism in women: roles of apoC-II and apoC-III.Plasma Proprotein Convertase Subtilisin Kexin Type 9 as a Predictor of Carotid Atherosclerosis in Asymptomatic Adults.ApoA-II HDL Catabolism and Its Relationships With the Kinetics of ApoA-I HDL and of VLDL1, in Abdominal Obesity.Effect of niacin on triglyceride-rich lipoprotein apolipoprotein B-48 kinetics in statin-treated patients with type 2 diabetes.Elevated lipoprotein(a), hypertension and renal insufficiency as predictors of coronary artery disease in patients with genetically confirmed heterozygous familial hypercholesterolemia.The effect of fenofibrate on HDL cholesterol and HDL particle concentration in postmenopausal women on tibolone therapy.Association of apolipoprotein M with high-density lipoprotein kinetics in overweight-obese men.Interrelationships between the kinetics of VLDL subspecies and HDL catabolism in abdominal obesity: a multicenter tracer kinetic study.Regulatory effects of HMG CoA reductase inhibitor and fish oils on apolipoprotein B-100 kinetics in insulin-resistant obese male subjects with dyslipidemia.Fat compartments and apolipoprotein B-100 kinetics in overweight-obese men.Effect of weight loss on postprandial lipemia and low-density lipoprotein receptor binding in overweight men.Plasma markers of cholesterol homeostasis and apolipoprotein B-100 kinetics in the metabolic syndrome.Effect of atorvastatin on apolipoprotein B48 metabolism and low-density lipoprotein receptor activity in normolipidemic patients with coronary artery disease.Angiographic progression of coronary atherosclerosis in patients with familial hypercholesterolaemia treated with non-statin therapy: Impact of a fat-modified diet and a resin.ATP-binding cassette transporter G8 gene as a determinant of apolipoprotein B-100 kinetics in overweight men.
P50
Q26824004-CF62BC49-6F59-4D12-83C6-F0C015BCB25DQ28185611-666D710B-D402-4E73-8482-82E1E1A26406Q33215989-7B1D783D-AA62-4F1D-8149-584CBB55A93FQ33804734-D6202209-4D48-47D9-85D5-0CE95860CD81Q34205994-41236C05-848D-4988-A668-8E6A3B747A4FQ34426322-D092BCDE-A7D6-4B98-8B1B-5EC2D0BFB0F3Q35754362-3CC7F9F4-DCED-4C42-A4F5-906A1A957E36Q35821941-D96C4129-7EDF-4546-9253-169E3868BB89Q36489934-1D266A26-CB0D-4965-AB03-E87368421FAFQ36572717-5AE8F5D0-7EB8-4F89-92AC-5A82ABAD594FQ36807515-8E6105DE-DAAB-4A6B-BA79-5A96E768978DQ36836003-C0F348F6-98A0-4432-BB24-6FEA264A35EAQ37311103-99F66022-52A7-4366-AC1C-05759CB031DFQ37326019-72DE7E74-0462-4CB5-89D5-CB3652016628Q37400800-98DF5893-BCBF-4945-915C-7B79739C06C7Q37434362-F7520DF4-9C94-4958-B9C3-D5EEDBFA69B4Q37505567-B8CAA3C9-48AD-43C5-9C56-4E66095CF051Q37938245-B19987C8-0521-400E-AE13-B3F213A9DC01Q38076370-07D20EF8-F9BD-4C77-9686-41B61CD4816AQ38141575-B7FC2FAF-0CCD-4274-A3CF-00F3635166A9Q38186099-1A4AF4A4-830B-4A05-845E-BCA094BEF38DQ38212739-E3CBB311-BB6D-45D1-8300-A85104B67A8BQ38268344-72B1B39D-45C8-464B-A947-F86D794ADA07Q38383623-64E85918-5ED3-49A6-BDA3-48173F16D36CQ38982733-7F0D4FFA-CAE8-42F2-87B6-1260B41BDB8BQ39631869-449B2EDC-AD53-4461-9F89-3ECE6DD01F80Q40169408-9B910DC3-8345-46F4-B92B-6D8FBDD842CCQ40936185-2494C65A-1992-4648-A151-D5634C99A5A7Q41041086-89AF4AA9-D78C-48E0-95B7-2F65868E72FCQ41412379-55B3FBEA-F6D3-4194-8EBC-82A7A449C58FQ43012977-8E4FBA56-B1CA-472F-A08A-877951D325C7Q43209712-357E0ED8-12F8-4963-AA7D-3A906B9E35C2Q43718524-54B8794E-CB42-4743-8BDC-44DF694E13B2Q44080980-609D68D4-4314-49A2-8CE3-8900D89934EEQ44279291-4FD13803-8FF4-4AA5-B6A2-F502C93CF0E9Q44325179-0379BE0E-6D3D-49B2-98F4-1EFB15942A75Q44400061-01383276-C7B2-4808-879E-96E248A42A5CQ44621504-3D5BE87E-F7C5-40BD-96C6-8D2AC1EDF5ADQ45020057-7BC325D3-D515-4927-96D2-79841CF4DEFAQ45032240-1FE41A08-6BFE-4171-B706-A10A44F0E1C1
P50
description
forsker
@nb
researcher ORCID ID = 0000-0001-7658-5197
@en
wetenschapper
@nl
name
D. Chan
@ast
D. Chan
@nl
Dick Chan
@en
Dick Chan
@es
Dick Chan
@nb
Dick Chan
@pt
type
label
D. Chan
@ast
D. Chan
@nl
Dick Chan
@en
Dick Chan
@es
Dick Chan
@nb
Dick Chan
@pt
altLabel
D. Chan
@en
prefLabel
D. Chan
@ast
D. Chan
@nl
Dick Chan
@en
Dick Chan
@es
Dick Chan
@nb
Dick Chan
@pt
P106
P1153
7402216503
P31
P496
0000-0001-7658-5197